The White House is poised to announce a drug pricing deal Thursday with Regeneron — the final holdout in the administration’s yearlong pressure campaign for more than a dozen pharmaceutical makers to discount drugs in exchange for tariff relief.

Regeneron has agreed to reduce Medicaid prices for its current and future medications, a White House official told NOTUS. The company has also agreed to sell Praluent, a drug used to lower cholesterol, for $225, the official said; it will be listed on President Donald Trump’s new drug pricing portal, TrumpRx, which connects Americans to discounts on certain drugs.

A source familiar with the deal said it includes Regeneron’s newest drug, Otarmeni, a gene therapy for children with a rare type of hearing loss. The company will announce it has received approval for the drug from the Food and Drug Administration, after it was fast-tracked last year. The company will offer the medication for free to anybody who needs it, the source said.

The Oval Office announcement, scheduled for Thursday afternoon, will feature a mother whose child used the drug and successfully regained their hearing.

Trump has made drug prices a central piece of his domestic policy agenda, writing last summer to 17 major pharmaceutical companies demanding they match the lowest drug prices paid by other developed nations — an initiative known as “Most Favored Nation.”

Regeneron was the last of the 17 companies to strike a deal with the administration.

Unlike some of the other pharmaceutical companies that cut White House deals, Regeneron makes only a few products and could take a heavier hit for discounting them.

The company has also agreed to boost its domestic manufacturing, committing almost $10 billion in spending to bring production capabilities to the United States, the official said.

Starting with an initial agreement with Pfizer in September, Trump has regularly ushered the companies’ executives into the Oval Office to highlight the deals and tout his efforts to lower drug prices in the United States, which are among the highest in the world.

Yet the deals may have a more limited impact than the administration claims.

Critics have noted that Medicaid already pays far less for drugs than Medicare and private insurers — which aren’t part of the deals — and many of the drugs featured on TrumpRx were already available at discounted prices. And some of the deal-making companies hiked prices on Jan. 1 anyway.

The deals were largely brokered by Chris Klomp, the head of Medicare, who was recently tapped to be a stabilizing influence at the Department of Health and Human Services ahead of the midterm elections. Since announcing those agreements, several companies have said they would give some of their products away for free to those in need. The White House has asked Congress to pass legislation requiring drugmakers to use “Most Favored Nation” pricing in government insurance programs.

Democrats pressed Health Secretary Robert F. Kennedy Jr. in a series of congressional hearings over the last week to disclose the terms of the pharmaceutical deals, which haven’t been made public, but Kennedy declined, citing “proprietary information.”

Trump received an antibody treatment made by Regeneron when he had COVID-19 during his first term.

Regeneron’s best-selling drug is Dupixent, an injectable used to treat severe eczema and a range of autoimmune conditions. The company’s other top drugs include Eylea, a treatment for macular degeneration, and Kevzara, a treatment for rheumatoid arthritis.